Teachers Advisors’s Carisma Therapeutics CARM Stock Holding History

Teachers Advisors’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-307	Closed	-$55K	–	3090
2015 Q1	$55K	Hold	307	–	–	﹤0.01%	3073
2014 Q4	$73K	Hold	307	–	–	﹤0.01%	3083
2014 Q3	$68K	Hold	307	–	–	﹤0.01%	3083
2014 Q2	$81K	Buy	307 +76	+33%	+$18.8K	﹤0.01%	3056
2014 Q1	$75K	Buy	+231	New	+$69.2K	﹤0.01%	3051

Other funds holding CARM

TRV

Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Teachers Advisors's CARM Position: Q2 2015 in Review

Teachers Advisors sold out of Carisma Therapeutics (CARM) in Q2 2015, closing a stake of 307 shares — an estimated $55K sold.

Teachers Advisors first reported a position in CARM in Q1 2014 and held it in 5 quarters. The position peaked at $81K in Q2 2014. 41 funds tracked by Wall St. Rank hold CARM as of Q2 2015.

Teachers Advisors reported no remaining Carisma Therapeutics position as of Q2 2015 after selling out during the quarter.
Teachers Advisors sold 307 Carisma Therapeutics shares in Q2 2015, an estimated $55K.
Teachers Advisors first reported a position in Carisma Therapeutics in Q1 2014 and held it in 5 quarters.
Teachers Advisors's Carisma Therapeutics position peaked at $81K in Q2 2014.
41 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2015.

Based on Teachers Advisors's 13F filing for Q2 2015, filed 10 Aug 2015.